Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Common Equity: 2016-2024

Historic Common Equity for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to -$8.8 million.

  • UroGen Pharma's Common Equity fell 552.31% to -$115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.4 million, marking a year-over-year decrease of 552.31%. This contributed to the annual value of -$8.8 million for FY2024, which is 86.50% up from last year.
  • As of FY2024, UroGen Pharma's Common Equity stood at -$8.8 million, which was up 86.50% from -$65.2 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Common Equity peaked at $96.4 million during FY2020, and registered a low of -$89.4 million during FY2022.
  • Its 3-year average for Common Equity is -$54.5 million, with a median of -$65.2 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 1,162.18% in 2022, then skyrocketed by 86.50% in 2024.
  • Yearly analysis of 5 years shows UroGen Pharma's Common Equity stood at $96.4 million in 2020, then tumbled by 91.27% to $8.4 million in 2021, then tumbled by 1,162.18% to -$89.4 million in 2022, then grew by 27.02% to -$65.2 million in 2023, then soared by 86.50% to -$8.8 million in 2024.